Despite recent advances, ovarian cancer remains the fifth leading cause of cancer-related deaths among women, and there's a critical need for new treatment options, especially for advanced cancers that grow back after standard ...
Apr 17, 2023
0
45
The Food and Drug Administration's recent approval of the drug olaparib for ovarian cancer patients with inherited mutations in the genes BRCA1 or BRCA2 came as welcome news to the thousands of women now eligible to receive ...
Feb 16, 2015
0
59
Researchers at The University of Texas MD Anderson Cancer Center have discovered that a combination of immune checkpoint blockade and targeted therapies that block normal DNA damage repair (DDR) achieved significant tumor ...
Feb 18, 2019
0
14
WEHI researchers have made a discovery that could help more Australian women with ovarian cancer gain access to game-changing cancer treatments called PARP inhibitors.
Jul 29, 2021
0
578
A study published today in Nature Communications shows that the drug rucaparib has been effective in treating certain types of ovarian cancers if used early in treatment, after a diagnosis, and before the cancer cells build ...
May 4, 2021
0
32
A pioneering precision medicine already licensed for breast and ovarian cancer can also slow or stop tumour growth in some men with advanced prostate cancer, a new clinical trial shows.
Dec 3, 2019
0
2
Scientists have identified a new class of targeted cancer drugs that offer the potential to treat patients whose tumors have faulty copies of the BRCA cancer genes.
Jun 17, 2021
0
24
Medications known as PARP inhibitors have emerged as a promising therapy for several forms of cancer fueled by a defect in the cells' DNA repair machinery. Yet many people with cancers caused by the defect, known as HR deficiency, ...
Apr 15, 2019
0
155
BRCA1 and BRCA2 ("BReast CAncer genes") are critical tumor suppressor genes—women carrying a mutation in one of these genes have up to an 80 percent risk of developing breast cancer and a 50 percent risk of developing ovarian ...
Jan 24, 2019
1
36
A rapid genetic testing model for patients with advanced prostate cancer can more quickly identify those with "actionable" gene variants eligible for newer targeted therapies, reports a clinical trial in The Journal of Urology.
Mar 29, 2023
0
3
